Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Mi2000 TICI - Post-market Implantation Study (TUPIS)

11 novembre 2026 aggiornato da: MED-EL Elektromedizinische Geräte GmbH

This Post-Market Clinical Follow-up (PMCF) investigation aims to further collect evidence on safety and performance of the Mi2000 TICI. This PMCF investigation will prospectively collect clinical data from the use of the Mi2000 TICI and related devices.

This PMCF investigation is performed on a cochlear implant system newly introduced to the market, which was previously studied in two pre-market clinical investigations. The purpose of the current clinical investigation is to collect further evidence by collecting additional clinical data on the use of the Mi2000 TICI.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

22

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Liège, Belgio, 4000
        • Non ancora reclutamento
        • Centre Hospitalier Universitaire de Liège, Department ORL
        • Contatto:
          • Philippe Lefebvre, Dr.med.
    • Belgium
      • Antwerp, Belgium, Belgio, 2650
        • Non ancora reclutamento
        • UZA Antwerpen
        • Contatto:
          • Vincent van Rompaey, Prof. Dr.
      • Würzburg, Germania
        • Non ancora reclutamento
        • Universitätsklinikum Würzburg
        • Contatto:
          • Kristen Rak, Prof. Dr.
    • Bavaria
      • München, Bavaria, Germania, 81377
        • Reclutamento
        • Klinikum der Universität München, Campus Großhadern
        • Contatto:
          • Joachim Müller, Dr.med.
    • Poland
      • Nadarzyn, Poland, Polonia, 05-830
        • Non ancora reclutamento
        • The Institute of Physiology and Pathology of Hearing
        • Contatto:
          • Piotr Skarzynski, Prof. Dr.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Minimum age of eighteen (18) years at time of enrolment
  • Bilateral sensorineural hearing loss with no or limited benefit from a hearing aid (>70 dB HL PTA4(500, 1000, 2000, 4000Hz))
  • Post-lingual onset of deafness
  • No or limited benefit from hearing aids for less than 10 years and an expected benefit from cochlear implantation
  • A maximum score of 50% on a word test in the language of the test center in the ear to be implanted in the best aided condition
  • Fluency in the test language with excellent proficiency, as appropriate to perform speech testing
  • Functional auditory nerve
  • General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study
  • Pre-operative assessment according to the local professional standards
  • Candidate is highly motivated and has realistic expectations about the expected benefit of the implant and shall understand the importance of returning to the implant center for regular speech processor programming, assessment sessions and training
  • Realistic expectations, as deemed appropriate by the implanting surgeon/implant board
  • Signed and dated informed consent before the start of any study-specific procedure

Exclusion Criteria:

  • Lack of compliance with any inclusion criterion

  • Previously having received an implant on the location chosen for placing the cochlear implant

  • Having received a hearing implant from another manufacturer than MED-EL on the contralateral ear

  • Pre-existing condition known to necessitate MRI scans after implantation of the Mi2000 TICI

  • Women being pregnant or nursing

  • The individual is known to be intolerant of the materials used in the implant or other required accessories

  • Absence of cochlear development

  • The cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway

  • Medical contra-indications to middle ear and/or inner ear surgery, and/or anesthesia

  • External or middle ear infections are present

  • The tympanic membrane is perforated in the ear to be implanted

  • Anatomic abnormalities are present that would prevent appropriate placement of the stimulator housing in the bone of the skull, or prevent placement of the chosen electrode array into the cochlea (including ossification of the cochlea)

  • The psychological status of the individual is unstable

  • The individual has unrealistic expectations

  • Acute cholesteatoma

  • History of vestibular schwannoma

  • Unstable Meniere's disease

  • Auditory Neuropathy

  • Epilepsy not responding to treatment

  • Permanent inability and/or unwillingness to participation in post-operative care and rehabilitation

  • Known intellectual disability and/or psychological diseases

  • Participation in other pharmacological clinical trials within four weeks prior to enrolment

  • Anything that, in the opinion of the Investigator, would

    • place the subject at increased risk
    • preclude the subject's full compliance with or completion of the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: TICI recipients

Participants in this clinical investigation will be implanted with an Mi2000 TICI totally cochlear implant

Participants in this clinical investigation will receive a totally implantable cochlear implant.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Word Test in Quiet
Lasso di tempo: Pre-op to 6 months after first fitting

Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes

Pre-op to 6 months after first fitting
Sentence Test in Noise
Lasso di tempo: Pre-op to 6 months after first fitting

Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes

Pre-op to 6 months after first fitting

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Health Utility Index Mark 3 (HUI3)
Lasso di tempo: Pre-op to 6 months after first fitting

Health utility scale:

1.00: Perfect health. 0.00: Death. Negative values: States worse than death.

Pre-op to 6 months after first fitting
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Lasso di tempo: Pre-op to 6 months after first fitting

Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes

Pre-op to 6 months after first fitting
Change in body sound perception
Lasso di tempo: through study completion, an average of 12 months after first fitting

Participant reported scale on body sound perception (0 - no disturbance to 10 - very disturbing)

through study completion, an average of 12 months after first fitting
Change in stigma perception
Lasso di tempo: through study completion, an average of 12 months after first fitting

Participant reported scale on stigma perception (0 - no stigmatization to 10 - strong stigmatization)

through study completion, an average of 12 months after first fitting
Change in comfort perception
Lasso di tempo: through study completion, an average of 12 months after first fitting

Participant reported scale on stigma perception (0 - not comfortable to 10 - very comfortable)

through study completion, an average of 12 months after first fitting

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Word test in quiet
Lasso di tempo: through study completion, an average of 12 months after first fitting

Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes

through study completion, an average of 12 months after first fitting
Sentence Test in Noise
Lasso di tempo: through study completion, an average of 12 months after first fitting

Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes

through study completion, an average of 12 months after first fitting
Health Utility Index Mark 3 (HUI3)
Lasso di tempo: through study completion, an average of 12 months after first fitting

Health utility scale:

1.00: Perfect health. 0.00: Death. Negative values: States worse than death.

through study completion, an average of 12 months after first fitting
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Lasso di tempo: through study completion, an average of 12 months after first fitting

Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes

through study completion, an average of 12 months after first fitting
Speech, Spatial, Quality of Hearing (SSQ12)
Lasso di tempo: through study completion, an average of 12 months after first fitting

Speech, Spatial and Quality of hearing scale from 0 to 10, higher numbers indicating better outcomes

through study completion, an average of 12 months after first fitting
Hearing Implant Sound Quality Index (HISQUI)
Lasso di tempo: through study completion, an average of 12 months after first fitting

Sound quality score ranging from 19 (very poor sound quality) to 133 (very good sound quality)

through study completion, an average of 12 months after first fitting
Tinnitus Functional Index (TFI)
Lasso di tempo: through study completion, an average of 12 months after first fitting

Tinnitus questionnaire measures the severity and negative impact of tinnitus on a 0 (Not a Problem / Slight Tinnitus) to 100 (Very Big Problem / Very Severe Tinnitus) scale

through study completion, an average of 12 months after first fitting
Audiogram
Lasso di tempo: through study completion, an average of 12 months after first fitting

Pure-tone air-conduction hearing thresholds will be measured in each ear. The threshold is the lowest sound level, in decibels hearing level (dB HL), at which the participant responds. The outcome is the threshold at each frequency. Higher thresholds mean poorer hearing; lower thresholds better hearing.

through study completion, an average of 12 months after first fitting

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Florian Schwarze, MED-EL

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 novembre 2026

Completamento primario (Stimato)

1 gennaio 2029

Completamento dello studio (Stimato)

1 gennaio 2029

Date di iscrizione allo studio

Primo inviato

15 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

22 ottobre 2026

Primo Inserito (Effettivo)

27 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi